about
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesRepression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophyThe δA isoform of calmodulin kinase II mediates pathological cardiac hypertrophy by interfering with the HDAC4-MEF2 signaling pathwayIsoflurane preconditioning and postconditioning in rat hippocampal neurons.Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administrationEpac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytesCardiac Protection of Valsartan on Juvenile Rats with Heart Failure by Inhibiting Activity of CaMKII via Attenuating Phosphorylation.beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation.Aging and CaMKII alter intracellular Ca2+ transients and heart rhythm in Drosophila melanogaster.Thyroid Hormone-Regulated Cardiac microRNAs are Predicted to Suppress Pathological Hypertrophic Signaling.Loss of the AE3 anion exchanger in a hypertrophic cardiomyopathy model causes rapid decompensation and heart failure.Fatty acid synthase modulates homeostatic responses to myocardial stress.IGF-2R-Gαq signaling and cardiac hypertrophy in the low-birth-weight lamb.Targeting cardiomyocyte Ca2+ homeostasis in heart failure.Systems-Pharmacology Dissection of Traditional Chinese Medicine Compound Saffron Formula Reveals Multi-scale Treatment Strategy for Cardiovascular Diseases.Is CaMKII a link between inflammation and hypertrophy in heart?Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction.βArrestins in cardiac G protein-coupled receptor signaling and function: partners in crime or "good cop, bad cop"?New antiarrhythmic targets to control intracellular calcium handling.Roles of Calcium Regulating MicroRNAs in Cardiac Ischemia-Reperfusion Injury.Pathways for CaMKII activation in disease.Inducible cardiomyocyte-specific deletion of CaM kinase II protects from pressure overload-induced heart failure.Molecular pathways underlying cardiac remodeling during pathophysiological stimulation.Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling.Induction of Lumen Formation in a Three-dimensional Model of Mammary Morphogenesis by Transcriptional Regulator ID4: ROLE OF CaMK2D IN THE EPIGENETIC REGULATION OF ID4 GENE EXPRESSION.Ca/Calmodulin-dependent Protein Kinase II in Heart Failure.Effects of acute and chronic sunitinib treatment on cardiac function and calcium/calmodulin-dependent protein kinase II.Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes.Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy.Functional and molecular factors associated with TAPSE in hypoxic pulmonary hypertension.Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKIIδ expression in the aged atrium.
P2860
Q26746907-AC18F9A3-A33E-4257-8B83-91D02CF71480Q28571438-06C44176-C115-4D9F-A89A-25B5523AFA60Q28582985-0CDFECA8-929E-479A-BB19-472C5BB81A60Q30430142-1F0D258B-00C6-4CFB-91E7-823DE43523ECQ33590761-6F2CAFA9-36CC-4F9A-8E04-A835BC626A70Q33631733-1767F7C1-1988-4989-AB56-1ED4EB2F8928Q33659776-28EC1B4A-7AA8-4CBB-8440-633D80D2E5DBQ33840022-BB501AB1-4359-45BF-8CCE-276CC9836FA2Q33864453-8A4C50F4-CF28-4323-922C-32A1D65177D7Q34369275-EA526199-3C96-4B65-BDFC-5A9371BBAB87Q34482398-D15F58A3-4FBC-407D-A6A6-BAD58AD35859Q35183031-4BA24A51-2846-43F5-9BFB-33D93961633BQ35275486-A19DAA34-BE9B-4438-842F-FC093F989655Q35763705-99CBE779-CE98-4322-BB07-6FB87469C399Q36506826-7BFCE9AD-DBBB-4366-A6CA-E4C8DEEB27C7Q37064322-A9C4038C-5C9D-411B-B064-9CE5640FCFF1Q37406363-AF5E23D1-31CB-43BC-9CC6-6E1025D979F8Q37421052-E8C1444D-124F-48D1-88CB-603815E839CBQ38204723-732D6FFA-8096-4905-8EBD-0C4913A7AD07Q38248649-7F66EB43-F971-48CC-BC2C-B756FE29C4D7Q38271033-43385B26-784D-4B17-A394-2D268F8ED979Q39341373-494C9549-344C-40E5-9BFE-372E105EACB0Q41855920-05F125A4-74C8-47CF-B39C-10430C5462EAQ41873666-516B728F-F1CE-42B3-821E-60EAD8B2BC11Q42110876-DA35A44F-F4AE-4902-BEF8-4C80A765A39AQ42717705-267FE4F1-04E0-4784-BC6C-16DAC2AAB6B4Q43019107-03D100A6-244C-4C15-89C6-ACEDD33E1D89Q47334714-9A107397-DA9F-48AD-9FF5-E218DA6472C2Q50890996-BCBDEF7F-AC1E-4B2F-82CB-8AA2BB295850Q51530668-AACF7657-0CB8-4A96-8B42-2D2C9F681D16Q52707811-07AE9E73-3F15-4855-BCCC-27FB9B657187
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
CaMKII and a failing strategy for growth in heart.
@en
CaMKII and a failing strategy for growth in heart.
@nl
type
label
CaMKII and a failing strategy for growth in heart.
@en
CaMKII and a failing strategy for growth in heart.
@nl
prefLabel
CaMKII and a failing strategy for growth in heart.
@en
CaMKII and a failing strategy for growth in heart.
@nl
P2860
P356
P1476
CaMKII and a failing strategy for growth in heart.
@en
P2093
Mark E Anderson
P2860
P304
P356
10.1172/JCI39262
P407
P577
2009-05-01T00:00:00Z